| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT01896999 |
| P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
| phase II clinical trial | Q42824440 | ||
| P17 | country | United States of America | Q30 |
| P582 | end time | 2025-03-20 | |
| P1050 | medical condition | lymphoma | Q208414 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 189 | |
| P4844 | research intervention | immunological antineoplastic agent | Q50429626 |
| P6153 | research site | Vanderbilt University | Q29052 |
| Johns Hopkins University | Q193727 | ||
| West Virginia University | Q115376 | ||
| University of North Carolina at Chapel Hill | Q192334 | ||
| Northwestern University | Q309350 | ||
| University of Alabama | Q492318 | ||
| Rutgers University | Q499451 | ||
| Southern Illinois University Edwardsville | Q519349 | ||
| Creighton University | Q770544 | ||
| Mayo Clinic | Q1130172 | ||
| Rush University Medical Center | Q1535116 | ||
| Denver Health Medical Center | Q3023367 | ||
| AdventHealth Porter | Q3145247 | ||
| Fox Chase Cancer Center | Q5476635 | ||
| Intermountain Medical Center | Q6047575 | ||
| Medical College of Wisconsin | Q6806307 | ||
| Memorial Medical Center | Q6815474 | ||
| Monmouth Medical Center | Q6901093 | ||
| Swedish Medical Center | Q7654755 | ||
| Tufts University School of Arts and Sciences | Q7851547 | ||
| University Medical Center of Southern Nevada | Q7894830 | ||
| University of Oklahoma Health Sciences Center | Q7896014 | ||
| Washington University School of Medicine | Q7972509 | ||
| Decatur Memorial Hospital | Q22033932 | ||
| MetroHealth Medical Center | Q30254005 | ||
| UNM Los Lunas | Q30258334 | ||
| 21st Century Oncology (United States) | Q30269404 | ||
| Sky Ridge Medical Center | Q30270451 | ||
| Jewish Hospital | Q30280293 | ||
| Aurora Sinai Medical Center | Q30280597 | ||
| Mercy Medical Center | Q30281132 | ||
| Comprehensive Cancer Centers of Nevada | Q30286943 | ||
| Colorado Blood Cancer Institute | Q43896855 | ||
| Aurora BayCare Medical Center | Q50036553 | ||
| Freeman Health System | Q50039515 | ||
| P580 | start time | 2014-01-24 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma |